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Introduction
Initial exposure to the varicella zoster virus 
(VZV) causes chickenpox (varicella). Upon 
recovery from the initial infection, VZV 
establishes latency and if reactivated, it will 
cause shingles (herpes zoster; HZ) (Gershon 
et al. 2010). As long as the host main-
tains sufficient VZV-specific cell-mediated 
immunity, the virus can remain latent indefi-
nitely. Approximately one of three people 
in the United States will develop HZ in 
their lifetime, resulting in > 1 million cases 
every year [Centers for Disease Control and 
Prevention (CDC) 2011a; Gershon et al. 
2010]. The risk of HZ increases in the elderly 
and in people with immuno suppressive 
illnesses and/or those taking immuno-
suppressive medications (CDC 2011a). Other 
risk factors for HZ include diabetes, female 
sex, Caucasian race, medical trauma, and 
psychological stress (Gershon et al. 2010).
Interestingly, medical case reports dating 
back to the early 1900s have documented the 
appearance of fine punctate irritating rashes, 
herpetic skin eruptions, and HZ in people 
shortly after they recovered from acute and 
sub chronic arsenic poisoning (Bartolomé 
et al. 1999; Carlill 1917; Hope-Simpson 
1965; Jacob 1931; Satterlee 1960; Uede 
and Furukawa 2003; Walsh 1900). More 
recently, clinicians have identified HZ as a 
common side effect for patients with acute 
promyelocytic leukemia (APL) after they 
received treatment with arsenic trioxide (Au 
and Kwong 2005; Douer and Tallman 
2005; Nouri et al. 2006; Rousselot et al. 
2004; Subbarayan et al. 2007; Tanvetyanon 
and Nand 2004). Although no study has 
been conducted to determine whether HZ 
is more common among APL patients who 
receive arsenic trioxide versus other treat-
ments, physicians have commented that 
only the patients treated with arsenic trioxide 
developed HZ (Tanvetyanon and Nand 
2004). There is evidence from animal models 
and in vitro studies that arsenic exposure can 
alter the immune response (Dangleben et al. 
2013). However, it is unknown whether 
exposure to arsenic from environmental 
sources affects the VZV immune response.
Currently, two National Health and 
Nutrition Examination Surveys (NHANES) 
included both VZV IgG serology testing and 
urinary arsenic measurements. Using these 
data, we sought to determine whether arsenic 
exposure in the general U.S. population is a 
risk factor for VZV IgG sero negativity. Our 
hypothesis was that higher urinary arsenic 
concentrations would be associated with a 
higher sero negative prevalence of VZV IgG.
Methods
Study population. The National Health and 
Nutrition Examination Survey (NHANES) 
is designed to be a nationally representative 
sample of the resident, noninstitutionalized 
U.S. civilian population. Participation rates 
for the 2003–2004 and the 2009–2010 cycles 
were 76% and 77.3%, respectively (CDC 
2013a). Informed consent was obtained from 
all survey participants, and all study protocols 
were approved by the National Center for 
Health Statistics research ethics review board 
(CDC 2013b).
In the present study, we restricted our 
analyses to individuals who had data on both 
VZV serology and urinary arsenic specia-
tion. Serological testing for VZV antibodies 
was performed on participants 6–49 years 
of age. Urinary arsenic concentrations 
were measured in a random sample of one-
third of the participants ≥ 6 years of age 
(Caldwell et al. 2009). This resulted in data 
on 1,641 individuals from the 2003–2004 
survey and 1,718 individuals from the 2009–
2010 survey. We excluded individuals with 
a positive test for human immuno deficiency 
virus (HIV; n = 4 for 2003–2004 and n = 7 
for 2009–2010) due to their compromised 
immune status. This resulted in a final sample 
size of 3,348 for the two pooled survey cycles.
Varicella zoster virus (VZV) serology. 
Initially, NHANES utilized an enzyme 
immuno assay method that detects disease-
acquired IgG anti bodies to VZV but is less 
sensitive to the IgG response produced by the 
vaccine (Reynolds et al. 2010). Subsequently, 
NHANES adopted a glycoprotein-based 
(gp) enzyme-linked immuno sorbent assay 
(ELISA) that is more sensitive and reliably 
detects both vaccine- and disease-induced 
immunity (Hammond et al. 2006). We 
utilized all available VZV data to ascertain 
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Background: Arsenic is an immunotoxicant. Clinical reports observe the reactivation of varicella 
zoster virus (VZV) in people who have recovered from arsenic poisoning and in patients with acute 
promyelocytic leukemia that have been treated with arsenic trioxide.
oBjective: We evaluated the association between arsenic and the seroprevalence of VZV IgG 
antibody in a representative sample of the U.S. population.
Methods: We analyzed data from 3,348 participants of the National Health and Nutrition 
Examination Survey (NHANES) 2003–2004 and 2009–2010 pooled survey cycles. Participants 
were eligible if they were 6–49 years of age with information on both VZV IgG and urinary arsenic 
concentrations. We used two measures of total urinary arsenic (TUA): TUA1 was defined as the 
sum of arsenite, arsenate, monomethylarsonic acid, and dimethylarsinic acid, and TUA2 was 
defined as total urinary arsenic minus arsenobetaine and arsenocholine.
results: The overall weighted seronegative prevalence of VZV was 2.2% for the pooled NHANES 
sample. The geometric means of TUA1 and TUA2 were 6.57 μg/L and 5.64 μg/L, respectively. 
After adjusting for age, sex, race, income, creatinine, and survey cycle, odds ratios for a negative 
VZV IgG result in association with 1-unit increases in natural log-transformed (ln)-TUA1 and 
ln-TUA2 were 1.87 (95% CI: 1.03, 3.44) and 1.40 (95% CI: 1.0, 1.97), respectively.
conclusions: In this cross-sectional analysis, urinary arsenic was inversely associated with VZV 
IgG seroprevalence in the U.S. population. This finding is in accordance with clinical observations 
of zoster virus reactivation from high doses of arsenic. Additional studies are needed to confirm the 
association and evaluate causal mechanisms.
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sero prevalence status across survey cycles 
to identify 98 sero negative and 3,250 sero-
positive individuals who were used in the 
combined analysis.
NHANES 2003–2004 .  VZV IgG 
was measured in serum using a whole cell 
enzyme immuno assay (EIA). This assay was 
developed by the Immunoserology Unit of 
the California State Department of Health 
Services Viral and Rickettsial Disease 
Laboratory and has been previously described 
(Forghani et al. 1978). This protocol yields 
an index of optical density (OD) reading, 
where an OD > 1 indicates the presence 
of the VZV antibody (sero positive) and an 
OD < 1 indicates that the antibody was not 
detected (sero negative). A negative VZV 
IgG test is useful to determine whether an 
individual is susceptible to infection by 
the virus (CDC 2011b). Subsequently, 
the CDC retested a subsample from this 
survey cycle using a gp-ELISA, which is 
considered to have higher sensitivity and 
specificity compared to the EIA method, 
and determined that the EIA produced false-
negative results for 26% of participants ages 
6–19 years (Reynolds et al. 2010). NHANES 
made the gp-ELISA data available in 2009. 
Subsequently, we used data from both the 
EIA and the available gp-ELISA to classify 
VZV status in this cycle. Specifically, the 
EIA and the gp-ELISA methods agreed on 
40 negative and 37 positive VZV individuals 
who were retested. Sixteen individuals who 
were initially identified as VZV negative by 
the EIA were reclassified as sero positive based 
on the gp-ELISA results. Finally, 14 indi-
viduals with an equivocal gp-ELISA result 
were left as initially identified by the EIA 
method. This resulted in 69 sero negative and 
1,568 sero positive individuals for this cycle.
NHANES 2009–2010. In this survey 
the CDC evaluated the presence of the VZV 
antibody using an EIA as described above. 
However, all samples that tested negative 
(OD < 1) or in the equivocal range were 
reevaluated using the gp-ELISA method. 
Therefore, all negative VZV IgG results in 
this survey were confirmed, yielding greater 
accuracy for the serological classification. This 
resulted in 29 sero negative and 1,682 sero-
positive individuals in this cycle.
Urinary arsenic assessment. Urinary 
arsenic concentrations were measured in a 
spot sample collected during the physical 
examination and analyzed within 3 weeks 
of collection using high-performance liquid 
chromatography (HPLC) coupled to induc-
tively coupled-plasma dynamic reaction 
cell–mass spectrometry (ICP-DRC-MS). 
Seven urinary arsenic species were evaluated 
with this method: arsenite (AsIII), arsenate 
(AsV), arsenobetaine (AsB), arsenocholine 
(AsC), monomethylarsonic acid (MMA), 
dimethylarsenic acid (DMA), and trimethyl-
arsine oxide, as well as total urinary arsenic 
(CDC 2007). The corresponding limits of 
detection (LODs) for the urinary arsenic 
species used were 0.4 μg/L, 0.6 μg/L, 
1.2 μg/L, 1.0 μg/L, 0.9 μg/L, and 1.7 μg/L 
for AsB, AsC, AsIII, AsV, MMA, and DMA, 
respectively. The LOD for total urinary 
arsenic in the 2003–2004 cycle was 0.6 μg/L 
and changed in the 2009–2010 cycle to 
0.74 μg/L. Samples with arsenic measure-
ments below the LOD were assigned a level 
equal to the LOD divided by the square root 
of two. The proportion of samples below the 
LOD in 2003–2004 was 44.57% for AsB, 
98.9% for AsC, 93.28% for AsIII, 92.61% for 
AsV, 60.26% for MMA, 11.46% for DMA, 
and 1.49% for total arsenic. In 2009–2010, 
the proportion of samples below the LOD 
was 37.14% for AsB, 98.2% for AsC, 
94.97% for AsIII, 97.29% for AsV, 67.39% 
for MMA, 19.93% for DMA, and 0.77% for 
total arsenic.
AsB and AsC are arseno sugars present in 
seafood and are considered to be non toxic 
(Mürer et al. 1992). We defined total urinary 
arsenic (TUA) using two approaches. The first 
approach (TUA1) was defined as the sum 
of AsIII, AsV, MMA, and DMA. The second 
approach (TUA2) was defined as total arsenic 
minus AsB and AsC. Because NHANES 
includes multiple demographic groups, it 
has been recommended that urinary analyte 
concentrations be evaluated as an unadjusted 
analyte concentration and have urinary creati-
nine as a separate independent variable to 
account for differences in urine dilution (Barr 
et al. 2005).
Adjustment variables. Variables that were 
considered in the analyses a priori as poten-
tial confounders for the association between 
VZV status and urinary arsenic concentra-
tions included age, sex, race/ethnicity, family 
poverty–income ratio, body mass index 
(BMI), urinary creatinine levels, and survey 
cycle. Race/ethnicity was self-reported as non-
Hispanic white, non-Hispanic black, other 
Hispanics, Mexican American, and other race 
including multiracial. “Other Hispanics” were 
collapsed into a single category with the other 
race category including multi racial for both 
survey cycles. BMI was calculated by dividing 
measured weight in kilograms by measured 
height in meters squared. BMI was classified 
as underweight (< 18.5), normal (18.5–24.9), 
overweight (25–29.9), and obese (≥ 30). For 
participants < 20 years of age, BMI classifi-
cation was defined using the CDC growth 
charts for age- and sex-specific cutoffs. 
Urinary creatinine was right-skewed and 
subsequently natural log (ln)-transformed.
Statistical analysis. All statistical analyses 
were performed in Stata using the survey 
command to account for the complex 
sampling design (version 12.1; StataCorp 
LP). Unweighted sample sizes are presented 
along with weighted prevalence and 
geometric means (GMs) for each covariates. 
Standard errors (SEs) and confidence intervals 
(CIs) were estimated using the Taylor linear-
ization method. The statistical significance 
level was set at α = 0.05, and all statistical 
tests were two-tailed. The association was 
evaluated for the two survey cycles inde-
pendently. The two survey cycles were also 
combined to increase the precision for the 
estimated relationship, and survey weights 
were rescaled to match the U.S. population at 
midpoint for the combined survey cycles.
TUA concentrations (TUA1 and TUA2) 
were right-skewed and ln-transformed for the 
analyses. Linear regression models were used 
to calculate the GM and SE of TUA by the 
prevalence of VZV status, and all covariates 
were evaluated for both survey cycles and for 
the combined sample. Associations between 
all covariates and urinary arsenic were evalu-
ated using a Wald test for significance to 
evaluate the overall association. The models 
estimating the GM of TUA for each strata 
always included urinary creatinine.
Logistic regression models were used to 
evaluate the association between sero negative 
VZV status and ln-TUA for the combined 
sample and for the two survey cycles inde-
pendently. This approach included all a priori 
covariates that were considered risk factors 
for VZV (e.g., age, sex, race/ethnicity, family 
poverty–income ratio, BMI), NHANES 
survey year, and ln-urinary creatinine. For the 
combined sample, we tested the interaction 
between survey cycle and arsenic exposure 
in the adjusted model. These interactions 
were not significant for TUA1 (p = 0.68) 
and TUA2 (p = 0.39), which suggested that 
the associations did not differ by survey year 
and further supported combining the two 
survey cycles. As a sensitivity analysis we 
also analyzed these logistic regression models 
without the sample weights (unweighted). 
This unweighted approach would prevent 
spurious associations that could result if a 
heavy weight was attached to few individuals. 
Further, weighted penalized splines were used 
to evaluate non linear relationships with knots 
at the 5th, 25th, 50th, and 95th percentiles of 
exposure. Because weighted penalized splines 
using the pooled data may produce unreli-
able 95% CIs, we used generalized additive 
models to evaluate non linear relationships 
and compute 95% CIs without including 
survey weights.
Results
Across both survey cycles, a total of 3,348 
participants had TUA1 measurements and 
3,283 participants had TUA2 measure-
ments. The difference in sample size (n = 65) 
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resulted from missing measurements used in 
computing TUA2. There were 98 individuals 
who were sero negative for the VZV IgG in 
the pooled study sample. For the pooled 
sample, the overall GM TUA1 and TUA2 
were 6.57 μg/L (95% CI: 6.26, 7.91 μg/L) 
and 5.64 μg/L (95% CI: 5.20, 6.12 μg/L), 
respectively. The population charac teristics 
for the pooled sample are provided in 
Table 1. TUA was significantly associated 
with race/ethnicity, age, and VZV serology 
based the overall creatinine-adjusted Wald 
test (Table 2). In the pooled sample, TUA1 
and TUA2 were slightly higher among 
VZV-sero negative IgG participants compared 
with sero positive individuals (8.31 μg/L 
vs. 6.77 μg/L, p = 0.01; and 7.62 μg/L vs. 
5.85 μg/L, p = 0.02). Only TUA1 was associ-
ated with BMI classification. The GMs of 
total urinary arsenic, which were adjusted for 
creatinine, were not different by sex or family 
poverty–income ratio (Table 2).
In adjusted models for the pooled 
survey sample, odds ratios (aORs) for 
a negative VZV IgG result in associa-
tion with 1-unit increases in ln-TUA1 and 
ln-TUA2 were 1.87 (95% CI: 1.03, 3.44) 
and 1.40 (95% CI: 1.0, 1.97), respectively 
(Table 3). These models were adjusted for 
age, ln-urinary creatinine, sex, race/ethnicity, 
family poverty–income ratio, BMI clas-
sification, and survey cycle. Because of the 
relatively small sample size and because some 
data were missing, we also analyzed the asso-
ciation between arsenic and VZV status using 
a more parsimonious approach that only 
controlled for age, survey cycle, and urinary 
creatinine. These models without as much 
missing data yielded consistent results where 
the odds of having a negative VZV result 
increased with each increase in ln-TUA1 
(aOR = 2.24; 95% CI: 1.37, 3.56) and 
ln-TUA2 (aOR = 1.58; 95% CI: 1.17, 2.13). 
Furthermore, the unweighted adjusted 
models yielded consistent results, suggesting 
that the observed association was not driven 
by spurious data that can result if a few indi-
viduals are given a greater weight. Finally, 
additional analysis that examined the associa-
tion between TUA and VZV sero prevalence 
in each survey cycle independently yielded a 
consistent association between negative VZV 
IgG sero prevalence and arsenic (Table 3).
The shape of the dose–response relation-
ship between TUA and VZV sero negative 
status was modeled using penalized splines 
as both weighted and unweighted samples 
(Figure 1). The shape of the dose–response 
relationships was approximately linear for 
unweighted spline models of TUA1 and 
TUA2 (Figure 1A and 1B, respectively). The 
weighted dose–response curves were more 
attenuated and non linear for TUA1 and 
TUA2 (Figure 1C and 1D, respectively). 
Despite these subtle differences in the shape 
of the dose–response curve between arsenic 
and VZV sero negative status, the weighted 
and unweighted analyses yielded a consistent 
positive association.
Discussion
In a representative sample of the U.S. popu-
lation 6–49 years of age, higher concentra-
tions of TUA were associated with a higher 
prevalence of negative VZV serology results 
after adjusting for other risk factors. Although 
the shape of the dose–response relationship 
could have been biased by accounting for 
urinary metabolites that were below the limit 
of detection, a significant positive association 
was observed in two NHANES surveys taken 
6 years apart, where the odds of a negative 
VZV result increased approximately 40–95% 
for each unit increase in TUA1 or TUA2. 
The association was consistent in the pooled 
analytic sample and across each survey cycle. 
These findings, which are the first to look at 
the association between arsenic exposures and 
VZV status in the U.S. general population 
and across a relatively modest range of expo-
sures, build upon prior experimental evidence 
and clinical observations that showed that 
therapeutic doses of inorganic arsenic affect 
and/or suppress specific immune functions; 
our findings also support the hypothesis that 
arsenic exposure diminishes VZV immunity. 
Arsenic is a common environmental 
contaminant that can be found in ground-
water and in the food chain. In our study, 
it was not possible to determine the route 
of arsenic exposure or the species of arsenic 
that comprised the exposure because only a 
spot urine sample was collected for arsenic 
measurement. However, in the United States, 
arsenic-contaminated drinking water is consid-
ered to be the dominant source of exposure 
and is mostly a concern for communities that 
rely on groundwater as their source of potable 
water [U.S. Environmental Protection Agency 
(EPA) 2001]. A 2001 study that used data 
collected by the U.S. EPA estimated that 
34 million Americans were drinking water 
with average arsenic concentrations > 50 μg/L, 
which was the maximum contaminant 
Table 1. Population characteristics [n (%)] for the combined NHANES 2003–2004 and 2009–2010 
presented as unweighted sample sizes and weighted percentages. 
Characteristic TUA1 TUA2
Total sample size (n) 3,348 3,283
Sex
Male 1,673 (50.3) 1,649 (50.6)
Female 1,675 (49.7) 1,634 (49.4)
Race
Non-Hispanic white 1,215 (62.7) 1,177 (62.3)
Non-Hispanic black 845 (12.9) 839 (13.1)
Mexican American 868 (12.1) 853 (12.2)
Other/Other Hispanic 420 (12.3) 414 (12.4)
Family poverty–income ratio
≤ 1 (below poverty level) 943 (19.6) 926 (80.2)
> 1 (above poverty level) 2,185 (81.4) 2,139 (19.8)
Missing 220 218
BMI (kg/m2)
< 18.5 (underweight) 86 (2.2) 85 (2.2)
18.5–24.9 (normal) 1,498 (41.2) 1,469 (41.0)
25–29.9 (overweight) 825 (28.0) 813 (28.1)
≥ 30 (obese) 909 (28.6) 916 (28.7)
Missing 30 23
Age (years)
6–11 514 (11.5) 534 (11.1)
12–19 1,002 (17.6) 1,063 (17.8)
≥ 20 1,598 (70.9) 1,686 (71.1)
TUA1 (μg/L)
≤ 4.8 (tertile 1) 1,032 (33.7) —
> 4.8 to 7.5 (tertile 2) 1,116 (32.3) —
> 7.5 to 139 (tertile 3) 1,200 (34.0) —
TUA2 (μg/L)
≤ 3.7 tertile 1 — 1,004 (33.0)
> 3.7 to 8.4 (tertile 2) — 1,132 (33.2)
> 8.4 to 300 (tertile 3) — 1,147 (33.8)
Creatinine (mg/dL)
≤ 80 (tertile 1) 960 (31.6) 917 (30.4)
> 80 to 153 (tertile 2) 1,122 (32.6) 1,113 (33.1)
> 153 to 768 (tertile 3) 1,263 (35.8) 1,253 (36.5)
VZV IgG
Seropositive 3,250 (97.8) 3,187 (97.8)
Seronegative 98 (2.2) 96 (2.9)
TUA1 = AsIII + AsV + MMA + DMA. TUA2 = Total As – AsC – AsB. 
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level (MCL) for drinking water at that time 
(Mushak 2000). In 2001, the U.S. EPA 
lowered the arsenic MCL to 10 μg/L because 
of concerns about elevated risk of internal 
cancers; municipalities had until 2006 to 
comply (Abedin et al. 2002). Private drinking-
water wells, however, are not monitored or 
regulated by the U.S. EPA, and survey data 
suggests that 11–19% of private wells exceed 
10 μg As/L (Focazio et al. 2006; Montgomery 
et al. 2003; Twarakavi and Kaluarachchi 
2006). Crops, particularly rice and cereal 
grains, can also take up arsenic from the soil 
and irrigation water (Cascio et al. 2011), and 
dietary sources of arsenic are receiving more 
attention as a result of data from recent studies 
indicating that people who regularly consume 
rice have higher urinary arsenic levels (Davis 
et al. 2012). It is possible that the lower 
exposure levels measured in the present study 
resulted from dietary intake. Although we were 
able to calculate a TUA concentration that did 
not include non toxic arseno sugars, the small 
sample size prohibited us from examining the 
association between VZV status and individual 
urinary arsenic metabolites.
There have been many clinical reports of 
VZV reactivation among people who have 
survived acute arsenic poisoning and among 
patients with acute promyleotic leukemia who 
have been treated with arsenic trioxide (Au 
and Kwong 2005; Bartolomé et al. 1999; 
Douer and Tallman 2005; Hope-Simpson 
1965; Nouri et al. 2006; Rousselot et al. 
2004; Subbarayan et al. 2007; Tanvetyanon 
and Nand 2004). Yet the biological mecha-
nisms by which this occurs are not well 
understood. Researchers have shown that 
arsenic trioxide prevents the loss of virions 
from the peri nuclear cell region, leading to 
an increase in cellular vector genome reten-
tion (Mitchell et al. 2013). There is also 
considerable evidence from in vitro and in vivo 
experimental studies that inorganic arsenicals 
are potent immuno toxicants. High doses of 
inorganic arsenic are known to suppress IgM 
and IgG antibody formation; inhibit antigen-
driven T-cell proliferation and macrophage 
activity; block the differentiation of monocytes 
into functional macrophages; decrease CD4+ 
splenic cell numbers; and alter the develop-
ment, activation, and proliferation of T cells 
(Bourdonnay et al. 2009; Burchiel et al. 
2009; Burns and Munson 1993; Conde et al. 
2007; Dangleben et al. 2013; de la Fuente 
et al. 2002; Galicia et al. 2003; Hernández-
Castro et al. 2009; Kozul et al. 2009a; 
Lemarie et al. 2006a, 2006b; Martin-Chouly 
et al. 2011; Nain and Smits 2012; Patterson 
et al. 2004; Sikorski et al. 1989; Soto-Peña 
et al. 2006; Yoshida et al. 1987). In addition, 
data from experimental models show that 
high doses of inorganic arsenic influence viral 
pathology (Dangleben et al. 2013; Kozul 
et al. 2009b; Martin-Chouly et al. 2011; 
Mitchell et al. 2013; Patterson et al. 2004; 
Ramsey et al. 2013; Sebastian et al. 2006). 
Less is known about the effects of methylated 
arsenical species on immuno logical outcomes.
The best way to reduce the risk of chicken 
pox and HZ is to be vaccinated for VZV. 
Since 1996, the Advisory Committee on 
Table 2. Weighted geometric mean (GM) and SE of total urinary arsenic (μg/L) by demographic characteristics in the NHANES 2003–2004 cycle, 2009–2010 
cycle, and a pooled sample (2003–2004 and 2009–2010).
Characteristic
2003–2004 2009–2010 Pooled
TUA1 
GM (SE)
TUA1  
p-Valuea
TUA2  
GM (SE)
TUA2 
p-Valuea
TUA1 
GM (SE)
TUA1 
p-Valuea
TUA2 
GM (SE)
TUA2 
p-Valuea
TUA1 
GM (SE)
TUA1 
p-Valuea
TUA2 
GM (SE)
TUA2 
p-Valuea
Seronegative (n) 69 69 29 29 98 98
Sex 0.27 0.94 0.09 0.01 0.58 0.15
Male 6.91 (1.05) 5.80 (1.09) 6.30 (1.03) 5.33 (1.04) 6.67 (1.03) 5.64 (1.05)
Female 6.96 (1.03) 5.83 (1.08) 6.68 (1.04) 5.94 (1.05) 6.77 (1.03) 5.95 (1.05)
Race < 0.001 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
Non-Hispanic white 6.42 (1.04) 5.23 (1.09) 5.92 (1.03) 5.28 (1.04) 6.23 (1.03) 5.22 (1.06)
Non-Hispanic black 6.52 (1.04) 5.63 (1.07) 6.00 (1.04) 5.22 (1.07) 6.31 (1.03) 5.40 (1.05)
Mexican American 7.89 (1.05) 6.85 (1.05) 7.19 (1.03) 5.77 (1.05) 7.34 (1.03) 6.25 (1.03)
Other/Other Hispanic 10.79 (1.06) 11.76 (1.10) 10.66 (1.10) 10.42 (1.08) 10.22 (1.05) 11.06 (1.07)
Family poverty–income ratio 0.69 0.95 0.54 0.15 0.53 0.39
≤ 1 (below poverty level) 6.87 (1.03) 5.84 (1.08) 6.40 (1.03) 5.84 (1.04) 6.69 (1.02) 5.81 (1.05)
> 1 (above poverty level) 7.00 (1.07) 5.87 (1.10) 6.55 (1.04) 5.34 (1.06) 6.82 (1.04) 5.60 (1.06)
BMI (kg/m2) 0.002 0.36 0.70 0.05 0.03 0.19
< 18.5 (underweight) 7.16 (1.09) 6.11 (1.08) 6.41 (1.16) 6.44 (1.15) 6.99 (1.06) 5.96 (1.04)
18.5–24.9 (normal) 7.17 (1.04) 6.11 (1.08) 6.52 (1.03) 5.82 (1.06) 6.85 (1.03) 6.97 (1.04)
25–29.9 (overweight) 6.93 (1.05) 5.84 (1.09) 6.56 (1.04) 6.20 (1.04) 6.86 (1.04) 5.94 (1.05)
≥ 30 (obese) 6.46 (1.03) 5.51 (1.07) 6.33 (1.03) 5.50 (1.04) 6.43 (1.02) 5.50 (1.04)
Age (years) 0.002 < 0.001 < 0.001 < 0.001 < 0.001 < 0.001
6–11 7.51 (1.06) 6.78 (1.11) 7.25 (1.03) 5.87 (1.06) 7.27 (1.04) 6.26 (1.06)
12–19 6.41 (1.05) 4.66 (1.07) 5.60 (1.03) 3.96 (1.05) 5.90 (1.03) 4.29 (1.04)
≥ 20 7.27 (1.04) 5.93 (1.08) 6.62 (1.03) 6.15 (1.04) 6.82 (1.03) 6.03 (1.04)
VZV IgG 0.08 0.06 0.004 0.02 0.01 0.02
Seropositive 7.09 (1.04) 6.16 (1.07) 6.47 (1.03) 5.61 (1.04) 6.77 (1.02) 5.85 (1.04)
Seronegative 8.61 (1.12) 8.21 (1.17) 8.18 (1.07) 7.62 (1.13) 8.31 (1.08) 7.62 (1.12)
TUA1 = AsIII + AsV + MMA + DMA. TUA2 = Total As – AsC – AsB. 
aModels adjusted for ln-transformed creatinine. 
Table 3. Adjusted odds ratios (aORs) and 95% CIs for seronegative VZV status in association with a 1-unit increase in ln-transformed TUA (μg/L) for the 
combined NHANES sample (2003–2004 and 2009–2010).
2003–2004 2009–2010 Pooled
Weighteda 
aOR (95% CI)
Unweighteda 
aOR (95% CI)
Weighteda 
aOR (95% CI)
Unweighteda 
aOR (95% CI)
Weightedb 
aOR (95% CI)
Unweightedb 
aOR (95% CI)
ln-TUA1 1.87 (1.05, 3.36) 2.03 (1.22, 3.37) 2.29 (1.49, 3.51) 1.92 (1.00, 3.71) 1.87 (1.03, 3.44) 1.95 (1.32, 2.90)
ln-TUA2 1.26 (0.97, 1.66) 1.36 (0.99, 1.89) 1.67 (1.17, 2.40) 1.44 (0.89, 2.33) 1.40 (1.00, 1.97) 1.37 (1.04, 1.79)
TUA1 = AsIII + AsV + MMA + DMA. TUA2 = Total As – AsB – AsC.
aModels adjusted for age, sex, race, family poverty–income ratio, BMI classification, and ln urinary creatinine. bModels adjusted for age, sex, race, family poverty–income ratio, BMI 
classification, ln urinary creatinine, and survey cycle. 
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Immunization Practices has recommended 
routine VZV vaccination of all children 
18 months to 2 years of age, susceptible 
adolescents, and adults that are at high risk 
of exposure to the virus (Marin et al. 2007). 
The vaccine contains live attenuated VZV, 
which is very effective and induces immunity 
in > 95% of the people who receive it 
(Reynolds et al. 2010). The vaccine results 
in latent infection, which can be reactivated 
and cause HZ, although studies have shown 
that the risk of reactivation after the vaccine is 
lower than for people who were infected with 
wild-type VZV (Reynolds et al. 2010). It 
would be useful for future studies to consider 
whether the arsenic–VZV sero prevalence 
association is only in those with wild-type 
VZV compared with people who have been 
vaccinated against VZV.
Important strengths of the present study 
include the use of a representative sample 
of the U.S. population exposed to arsenic 
at environmental concentrations. We also 
used urinary biomarkers to assign personal 
exposure levels of arsenic. Further we 
adjusted for relevant risk factors for VZV and 
urinary arsenic concentrations. The rigorous 
quality control procedures implemented in 
NHANES is also an important strength of 
the quality of the data presented. Although 
the protocol for the VZV assay changed 
between cycles, there was improved preci-
sion in the data collected in 2009–2010, 
which is likely a function of the gp-ELISA 
for determining VZV status. This assay has 
a higher sensitivity and specificity for VZV 
antibodies produced by vaccination, which 
likely accounts for the more precise ORs in 
this cycle, even though the actual number of 
VZV-sero negative samples was lower. Finally, 
the reproduci bility of the effect and the obser-
vation of an exposure–response relationship 
between increasing TUA concentration and 
VZV serology in two different survey cycles 
is reassuring.
There are also limitations to our study 
that must be considered. NHANES is a cross-
sectional study, and the temporality between 
arsenic exposure and VZV serology cannot be 
assessed. NHANES measures urinary arsenic 
concentrations only in one-third of the partici-
pants, and urinary arsenic metabolites have a 
relatively short half-life, which limits their use 
for estimating historical or long-term expo-
sures (Buchet et al. 1981). The presence of 
unmeasured confounders cannot be ruled out 
because serum-specific IgG response resulting 
from vaccination or natural infection could be 
modified by other immune-suppressive condi-
tions or chronic infections. Yet, we accounted 
for several important risk factors in the popu-
lation, including age, race, sex, and BMI. Also, 
the sero negative VZV prevalence was low in 
both cycles for our combined sample. It is 
possible that participants who were infected 
with VZV previously but did not mount a 
sufficient IgG response that could allow for 
accurate serology testing could have been 
misclassified. Furthermore, a negative VZV 
IgG result could indicate that an individual 
has not been previously infected with the 
virus and that arsenic exposure was protective. 
This interpretation, however, seems unlikely 
because arsenic is known to be immunotoxic, 
clinical reports have noted VZV reactivation 
after arsenic exposure, an estimated 99.5% 
of people born in the United States who are 
≥ 40 years of age have serological evidence 
of previous VZV, and VZV vaccines were 
widely adopted after 1996 (CDC 2012). 
Unfortunately, there was no available infor-
mation on other anti bodies, such as IgM, to 
improve our classification of VZV status. We 
were also not able to evaluate the observed 
Figure 1. Adjusted odds ratios (aORs) from penalized spline models for negative VZV IgG by TUA. (A) TUA1 unweighted. (B) TUA2 unweighted. (C) TUA1 weighted. 
(D) TUA2 weighted. aORs are based on penalized splines for ln-transformed total arsenic exposure. Models fully adjusted for age, ln-urinary creatinine, sex, race/
ethnicity, family poverty–income ratio, BMI classification, and survey cycle. (A) and (B) are unrestricted splines with 95% CIs; (C) and (D) were estimated from 
weighted models restricted to knots at the 5th, 25th, 50th, and 95th percentiles of exposure. TUA1 = AsIII + AsV + MMA + DMA. TUA2 = Total As – AsC – AsB. 
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association in children < 6 years of age or 
adults > 45 years of age. VZV reactivation 
is a common problem among older adults, 
with the incidence of zoster increasing at 
50–60 years, so the impact of arsenic exposure 
on this group may be different (Harpaz 
et al. 2008).
Conclusions
TUA concentration was positively associated 
with sero negative VZV IgG prevalence in a 
population with modest arsenic exposure. 
This information builds upon experimental 
studies and clinical observations showing 
an association between acute exposures to 
high levels of arsenic with herpes zoster 
and supports a link between environmen-
tally relevant levels of arsenic exposure and 
VZV-specific immune response. Additional 
studies are needed to more fully evaluate 
the effect of arsenic on other parameters of 
immune functioning and its ability to cause 
VZV reactivation. From a public health 
perspective, confirmation of arsenic’s ability 
to suppress specific immune functioning 
has important implications for vaccine-
preventable illnesses.
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